Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Enters Cancer Biologics Deal With Oxford Genome Sciences

This article was originally published in The Pink Sheet Daily

Executive Summary

Collaboration is the second in recent months to involve Amgen’s XenoMouse human monoclonal antibody generating technology.

You may also be interested in...



Deal Watch: Lundbeck Acquires Chelsea As Industry Awaits Possible AstraZeneca, Allergan Buyouts

Merck sells off its consumer business to Bayer AG in a deal in which the two companies also will co-develop and co-commercialize sGC modulator drugs. Lundbeck buys out Chelsea and its recently approved dizziness drug Northera.

GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies

Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.

GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies

Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel